Plant Name: Firmiana simplex
Taxonomic Information:
Plant ID: NPO12068
Plant Latin Name: Firmiana simplex
Taxonomy Genus: Firmiana
Taxonomy Family: Malvaceae
Plant External Links:
NCBI TaxonomyDB:
190243
Plant-of-the-World-Online:
823357-1
Used in Medicines:
Country/Region:
ChinaTraditional Medicine System:
TCMMedicinal Functions:
Antiphlogistic; Astringent; Expectorant; Refrigerant; Salve
Geographical Distribution:
United States; South Africa; Mauritius; Vietnam; China; Japan; Taiwan
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA2C; ADRA2A; | |
| TSHR; NMUR2; | |
| GAA; ACHE; | |
| KCNH2; | |
| MAPK1; | |
| NR1H4; | |
| SCD; POLB; | |
| TP53; | |
| SLCO1B3; SLCO1B1; | |
| SMN1;SMN2; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | SCD | Acyl-CoA desaturase | O00767 | CHEMBL5555 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Potassium channels | KCNH2 | HERG | Q12809 | CHEMBL240 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0051179; localization | GO:0015721; bile acid and bile salt transport | 3.221E-06 | 2.491E-02 | NR1H4, SLCO1B1, SLCO1B3 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 5.494E-06 | 2.491E-02 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 5.494E-06 | 2.491E-02 | ADRA2A, ADRA2C |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 2.748E-06 | 2.491E-02 | ADRA2A, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.372E-05 | 2.987E-02 | CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 2.558E-05 | 4.284E-02 | ADRA2A, ADRA2C |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.881E-05 | 4.482E-02 | ADRA2A, SLCO1B1, SLCO1B3, TSHR |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 3.988E-05 | 4.945E-03 | SLCO1B1, SLCO1B3, NR1H4 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.185E-04 | 6.414E-03 | NMUR2, ADRA2C, ADRA2A, TSHR |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.552E-04 | 6.414E-03 | CYP2C9, MAPK1, CYP2C19 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 2.996E-04 | 7.065E-03 | LMNA, MAPK1, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 5.022E-04 | 8.896E-03 | MAPK1, ADRA2C, ADRA2A |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 3.419E-04 | 7.065E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 9.110E-04 | 1.255E-02 | POLB, MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 6.858E-04 | 1.063E-02 | MAPK1, TP53 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.419E-04 | 7.065E-03 | CYP2C9, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 1.102E-03 | 1.367E-02 | MAPK1, TP53 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | SCD; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ACHE; TP53; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | SCD; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | SCD; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | SCD; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
